연구용
제품 번호: S1017
화학 구조
| 세포주 | 분석 유형 | 농도 | 배양 시간 | 제형 | 활성 설명 | PMID |
|---|---|---|---|---|---|---|
| HUVEC cell | Proliferation assay | 3 days | Inhibition of VEGF-stimulated HUVEC cell proliferation treated before 2 hrs of VEGF challenge assessed after 3 days by [3H]thymidine incorporation assay, ED50=12 nM | 19101155 | ||
| HeLa | Function assay | 4.5 hrs | Inhibition of Ebolavirus glycoprotein/matrix protein VP40 entry in human HeLa cells after 4.5 hrs beta-lactamase reporter assay, IC50=7.67μM | 29624387 | ||
| DAOY | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells | 29435139 | |||
| SJ-GBM2 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells | 29435139 | |||
| A673 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells | 29435139 | |||
| BT-37 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells | 29435139 | |||
| NB-EBc1 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells | 29435139 | |||
| Saos-2 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells | 29435139 | |||
| SK-N-SH | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells | 29435139 | |||
| LAN-5 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells | 29435139 | |||
| BT-12 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells | 29435139 | |||
| Rh18 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells | 29435139 | |||
| OHS-50 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells | 29435139 | |||
| RD | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells | 29435139 | |||
| MG 63 (6-TG R) | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells | 29435139 | |||
| fibroblast cells | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells | 29435139 | |||
| Rh30 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells | 29435139 | |||
| Rh41 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells | 29435139 | |||
| 클릭하여 더 많은 세포주 실험 데이터 보기 | ||||||
| 분자량 | 450.51 | 화학식 | C25H27FN4O3 |
보관 (수령일로부터) | |
|---|---|---|---|---|---|
| CAS 번호 | 288383-20-0 | SDF 다운로드 | 원액 보관 |
|
|
| 동의어 | NSC-732208 | Smiles | CC1=CC2=C(N1)C=CC(=C2F)OC3=NC=NC4=CC(=C(C=C43)OC)OCCCN5CCCC5 | ||
|
In vitro |
DMSO
: 90 mg/mL
(199.77 mM)
Ethanol : 6 mg/mL Water : Insoluble |
|
In vivo |
|||||
1단계: 아래 정보 입력 (권장: 실험 중 손실을 고려하여 추가 동물 포함)
2단계: 생체 내 제형 입력 (이것은 계산기일 뿐 제형이 아닙니다. 용해도 섹션에 생체 내 제형이 없는 경우 먼저 당사에 문의하십시오.)
계산 결과:
작업 농도: mg/ml;
DMSO 원액 준비 방법: mg 약물 사전 용해 μL DMSO ( 원액 농도 mg/mL, 농도가 해당 약물 배치의 DMSO 용해도를 초과하는 경우 먼저 당사에 문의하십시오. )
생체 내 제형 준비 방법: 취하다 μL DMSO 원액, 다음 추가μL PEG300, 혼합하고 투명하게 한 다음 추가μL Tween 80, 혼합하고 투명하게 한 다음 추가 μL ddH2O, 혼합하고 투명하게 합니다.
생체 내 제형 준비 방법: 취하다 μL DMSO 원액, 다음 추가 μL 옥수수 기름, 혼합하고 투명하게 합니다.
참고: 1. 다음 용매를 추가하기 전에 액체가 투명한지 확인하십시오.
2. 용매를 순서대로 추가해야 합니다. 다음 용매를 추가하기 전에 이전 추가에서 얻은 용액이 투명한 용액인지 확인해야 합니다. 와동, 초음파 또는 뜨거운 물 중탕과 같은 물리적 방법을 사용하여 용해를 도울 수 있습니다.
| Targets/IC50/Ki |
VEGFR2/KDR
(HUVECs) 0.5 nM
c-Kit
(HUVECs) 2 nM
VEGFR3/FLT4
(HUVECs) <=3 nM
VEGFR1/FLT1
(HUVECs) 5 nM
PDGFRβ
(HUVECs) 5 nM
FGFR1
(HUVECs) 26 nM
PDGFRα
(HUVECs) 36 nM
|
|---|---|
| 시험관 내(In vitro) |
Cediranib (AZD2171) inhibits VEGF-stimulated proliferation with IC50 of 0.4 nM and suppresses PDGF-AA with IC50 of 0.04 μM in MG63 cell lines. It has been shown to block Flt1-associated kinase with IC50 of 5 nM and VEGF-C and VEGF-D receptor Flt-4 with IC50 less than 3 nM. In addition, the IC50 values for inhibition of c-Kit and PDGFRβ tyrosine kinase are 2 nM and 5 nM respectively. Furthermore, no inhibition of enzyme activity is observed when 10 μM of this compound is assayed with 100 μM ATP against AMPK, Chk1 Akt/PKB and others. Micromolar concentrations are needed to prevent tumor cell proliferation in vitro.
|
| 키나아제 분석 |
Kinase 억제
|
|
Cediranib (AZD2171)은 DMSO에 10 mM 농도로 용해됩니다. 모든 효소 분석은 ATP에 대한 각 Km(0.2 - 30 μM)에서 또는 그 바로 아래에서 실행됩니다. 이 화합물의 억제 활성은 ELISA를 사용하여 다양한 재조합 티로신 키나아제[KDR, Flt-1, Flt-4, c-Kit, PDGFRα, PDGFRβ, CSF-1R, Flt-3, FGFR1, Src, Abl, epidermal growth factor receptor (EGFR), ErbB2, Aurora A 및 Aurora B]에 대해 결정됩니다. CDK2 및 CDK4 세린/트레오닌 키나아제에 대한 선택성은 망막모세포종 기질 및 [γ-33P]ATP를 사용하는 섬광 근접 분석(scintillation proximity assays)을 통해 조사됩니다. 이 화합물의 활성은 이중 특이성을 나타내는 MAPK 키나아제(MEK)와 비교됩니다. 이는 MAPK 기질, [γ-33P]ATP 및 종이 포집/섬광 계측을 사용하여 결정됩니다.
|
|
| 생체 내(In vivo) |
Cediranib (AZD2171) even suppresses tubule sprouting at subnanomolar concentrations and inhibits VEGF-induced angiogenesis. This compound causes hypertrophy in bone growth plate and prevents luteal development in ovary. These are physiological processes that are dependent upon angiogenesis. It shows broad spectrum activity in human tumor models at doses that are well tolerated. Besides, it causes regression of vascular tissues in human lung tumor xenografts.
|
참조 |
|
| 방법 | 바이오마커 | 이미지 | PMID |
|---|---|---|---|
| Western blot | BRCA2 / BRCA1 / RAD51 p-VEGFR1 / p-VEGFR3 / p-AKT / p-ERK |
|
31092693 |
(데이터 출처 https://clinicaltrials.gov, 업데이트 날짜 2026-03-05)
| NCT 번호 | 모집 | 조건 | 스폰서/협력자 | 시작일 | 단계 |
|---|---|---|---|---|---|
| NCT04090567 | RECRUITING | Advanced Breast Carcinoma; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IIIA Breast Cancer AJCC v8; Anatomic Stage IIIB Breast Cancer AJCC v8; Anatomic Stage IIIC Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Germline BRCA1 Gene Mutation; Germline BRCA2 Gene Mutation; HER2/Neu Negative; Metastatic Breast Carcinoma; Prognostic Stage III Breast Cancer AJCC v8; Prognostic Stage IIIA Breast Cancer AJCC v8; Prognostic Stage IIIB Breast Cancer AJCC v8; Prognostic Stage IIIC Breast Cancer AJCC v8; Prognostic Stage IV Breast Cancer AJCC v8 |
M.D. Anderson Cancer Center |
2020-07-28 | PHASE2 |
| NCT02484404 | ACTIVE_NOT_RECRUITING | Colorectal Neoplasms; Breast Neoplasms |
National Cancer Institute (NCI) |
2015-06-29 | PHASE1; PHASE2 |
| NCT03851614 | ACTIVE_NOT_RECRUITING | Mismatch Repair Proficient Colorectal Cancer; Pancreatic Adenocarcinoma; Leiomyosarcoma |
University Health Network, Toronto |
2019-04-08 | PHASE2 |
| NCT03741426 | UNKNOWN | Renal Cell Cancer |
CCTU- Cancer Theme |
2020-07-27 | PHASE2 |
| NCT04487587 | ACTIVE_NOT_RECRUITING | Cervical Cancer |
The Clatterbridge Cancer Centre NHS Foundation Trust |
2018-10-09 | PHASE2 |
| NCT07648745 | COMPLETED | Bowel Obstruction; Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Cancer |
Prof Gordon Jayson |
2018-05-14 | PHASE2 |